Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Status:
Terminated
Trial end date:
2013-07-08
Target enrollment:
Participant gender:
Summary
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal
antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry
cancer-killing substances to them without harming normal cells. Giving bortezomib together
with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.
This phase I/II trial is studying the side effects and best dose of bortezomib when given
together with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work
in treating patients with relapsed or refractory follicular non-Hodgkin's lymphoma.